Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has been reported to be an effective treatment approach for peritoneal cancer, however, the stress response to HIPEC is major neuroendocrine and cytokine response, which has been considered as the homeostatic defense mechanism. Recently, dexmedetomidine has been suggested to exhibit anti-inflammatory properties. This study was designed to evaluate the effect of perioperative administration of dexmedetomidine on inflammation response and postoperative outcomes in patients undergoing hyperthermic intraperitoneal chemotherapy (HIPEC) cytoreductive surgery.

Inclusion Criteria:

• patients between 20 and 70 years old
• obtaining written informed consent from the patients who were undergoing hyperthermic intraperitoneal chemotherapy (HIPEC) cytoreductive surgery
• weights under 90 kg and BMI under 32

Exclusion Criteria:

• emergency operation
• re-operations
• combined surgery over 4 departments.
• cardiac disease (unstable angina, congestive heart failure, valvular heart disease)
• Ventricular conduction abnormality
• prior pacemaker insertion
• uncontrolled hypertension (diastolic blood pressure > 110mmHg)
• bradycardia (HR < 40 Bpm)
• cerebral vascular disease (cerebral hemorrhage, cerebral ischemia)
• hepatic or renal failure
• patients who take antiarrythmic agent
• neurological or psychiatric illnesses
• foreigner and patient who can not read the letter

Investigator prepared the drug and participant and outcomes assessor were blind to the group allocation